Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.


BACKGROUND In patients with metastases limited to the liver (liver-limited disease [LLD]), effective therapies such as monoclonal antibodies combined with chemotherapy may facilitate metastasis resection and improve long-term survival. OBJECTIVE This study assessed the cost-effectiveness of bevacizumab and cetuximab in the treatment of patients with… (More)
DOI: 10.1016/j.clinthera.2011.04.010


12 Figures and Tables